As the treatment landscape for #NMIBC continues to evolve, get the insights you need to know with Medthority. Log in to hear from Joshua Meeks, Félix Guerrero-Ramos, and @ashishkamatmd.bsky.social, plus catch up with highlights from #ESMO25, #ASCO25, and more! #MedSky #OncSky
ow.ly/mFcc50XZKzO
“I think this is tremendous. Now immunotherapy will be here and present for our head and neck [cancer] patients undergoing cancer resection,” said @danafarbernews.bsky.social’s Glenn Hanna, MD, in an Oncology Times article describing clinical trials presented at #ASCO25 and #AACR25. bit.ly/4qF4ID9
A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care.
https://bit.ly/3XBFHfA
#leusm #ASCO25
Local collaboration, global recognition
FT3’s partner Project Pink Blue (Nigeria) presented new findings at #ASCO25 showing how education & advocacy strengthen precision oncology access and communication.
Read the study 👉 tinyurl.com/4np3rad2
Learn more 👉 tinyurl.com/4a9z96ss
#PrecisionMedicineMonth
Now Available: Best of Alliance at ASCO 2025 Webinar. Catch Alliance for Clinical Trials in Oncology investigators sharing key takeaways from five studies on colorectal, squamous cell, and renal cell cancers at #ASCO25. Watch at https://bit.ly/Alliance-At-ASCO American Society of Clinical Oncology
A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care. From #ASCO25.
https://bit.ly/4ib5gh0
#leusm #lymsm
Dr. Charbel Matar highlights practical guidance shared by experts across community, private, and hospital-based oncology settings at an #ASCO25 Trainee and Early Career Lounge session.
Read more: brnw.ch/21wXiJk
#ASCOConnection
Dr. Charbel Matar highlights practical guidance shared by experts across community, private, and hospital-based oncology settings at an #ASCO25 Trainee and Early Career Lounge session.
Read more: brnw.ch/21wXimz
#ASCOConnection
Dr. Faith Abodunrin highlights candid reflections on navigating workload, career development, and the ever-evolving challenge of balance, shared by panelists of an #ASCO25 Trainee and Early Career Lounge session.
Read more: brnw.ch/21wXe8h
#ASCOConnection
Dr. Shreyas Kalantri highlights practical guidance on navigating contract negotiations for early-career oncologists, shared by panelists during an #ASCO25 Trainee and Early Career Lounge session.
Read more: brnw.ch/21wWS9B
#ASCOConnection
🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses sequencing IO and radiotherapy in nasopharyngeal carcinoma:
➡️ buff.ly/K24ba3d ⬅️
#ASCO25 #ImmunOnc #hncSM
From the Trainees and Early Career Lounge at #ASCO25 -Research 101: Identifying a Research Question and Selecting an Appropriate Study Design | @ascocancer.bsky.social connection.asco.org/do/research-...
⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:
🎥 buff.ly/0IeuM2Z
@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc
⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:
🎥 buff.ly/FJvSAAR
@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc
⭐ Michael Gnant, MD, FACS, reviews long-term endocrine therapy in HR+ breast cancer: benefit for high-risk pts, ovarian suppression in ASTRRA, & elinzanetant for vasomotor symptoms:
🎥 buff.ly/hfp5orD
@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #CTSM #TrialUpdate
Our annual Review of Advances in Oncology: Highlights from the @ascocancer.bsky.social Annual Meeting #ASCO25 begins! We’re looking forward to a full day of updates and connections.
🎥 Samer Srour, MB ChB, MS, of @mdanderson.bsky.social, discusses IVS-3001, an autologous CAR T targeting HLA-G in advanced solid tumors. Phase I/IIa trial evaluates safety, PK, and early efficacy:
Watch➡️https://buff.ly/KsUmJh8
@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate
🎥Nadia Hindi, MD, highlights challenges in comparing ICIs vs antiangiogenic therapy in ultra-rare sarcomas. Limited data & lack of pure monotherapy cohorts make conclusions difficult—randomized trials are needed:
➡️https://buff.ly/utlNO0r⬅️
@ascocancer.bsky.social #ASCO25 #ImmunoOnc #scmSM
7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients
↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going
5/ PERSEUS #ASCO25: sustained MRD- in pts on quad maintenance median follow-up of 47.5m
👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx
🎥Can biomarkers guide T-DXd use in metastatic breast cancer?
⭐ Paolo Tarantino, MD, of @danafarber.bsky.social
reports:
🔹More HER2 mRNA/protein → longer benefit
🔹High Topo1 → worse outcomes in HER2⁻ disease
➡️https://buff.ly/G4wnu14
@ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #ImmunoOnc
🎥 Dr Suneel Kamath from @clevelandclinic.bsky.social addresses cancer research funding disparities: current allocation driven by advocacy.
➡️Proposes burden-based, criteria-driven approach to ensure equity across diseases
Watch🔗https://buff.ly/d2uKbEB
@ascocancer.bsky.social #ASCO25 #Oncology
🎥Dr Inimfon Jackson from @mdanderson.bsky.social
discusses disparities in chemo acceptance:
➡️Greatest in uninsured/publicly insured & Black patients. Advocates trust-building, early risk ID & informed decision support.
🔗 buff.ly/nttGH5r
@ascocancer.bsky.social #ASCO25 #Oncology
🎥 @janichinmay.bsky.social explores alcohol’s role in cancer mortality:
➡️Calls for age/geography–stratified analyses & focus on mechanisms incl. microbiome & ICI interaction.
Learn more here🔗 buff.ly/zcvqHJd
@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc
🎥 Xiaoqian Nie, PhD, reports Phase I data:
➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy
🔗 buff.ly/cD7UDXr
@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate
🎥 Dr John Paul Shen (@mdanderson.bsky.social) compares methylation-based tissue-free ctDNA assays vs tissue-reliant approaches.
➡️ Sensitivity varies by tumor site & mutation profile—trials needed to define accuracy in MRD detection.
🔗 buff.ly/cGkX0l2
@ascocancer.bsky.social #ASCO25 #Oncology
🎥 Prof. Francois Doz (@institutcurie.bsky.social) emphasizes precision medicine in pediatric cancer
➡️Trials like iMATRIX Alectinib show promise, but rapid molecular profiling at diagnosis remains a barrier to real-world adoption.
🔗 buff.ly/qJueBU3
@ascocancer.bsky.social #ASCO25 #Oncology #CTSM
🎥 Manmeet Ahluwalia, MD, notes the shift in brain metastasis care: from surgery & WBRT ➡️ targeted therapies & ICIs. Next: combinations with ADCs + ICIs while balancing radiation toxicity.
🔗 buff.ly/Q988SOT
@ascocancer.bsky.social #ASCO25 #ImmunoOnc #Oncology #SurgOnc
